Yesterday, a Director at Ligand Pharma (LGND), Sunil Patel, bought shares of LGND for $95.98K.
This recent transaction increases Sunil Patel’s holding in the company by 3.94% to a total of $2.36 million. In addition to Sunil Patel, 3 other LGND executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
LGND’s market cap is $1.75B and the company has a P/E ratio of 2.85. Currently, Ligand Pharma has an average volume of 700.2K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $154.67, reflecting a 72.8% upside.
In the last 30 days, insiders have sold $386.4K worth of LGND shares and purchased $366.2K worth of LGND shares. The insider sentiment on Ligand Pharma has been positive according to 59 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
